As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...

Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma.

Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$1,319 Current share ...

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

Lupin had been marketing Huminsulin through an existing agreement with Lilly India before proceeding to acquire the brand. Huminsulin is used in the treatment of Type 1 and Type 2 diabetes mellitus.

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...